Is Lineage Cell Therapeutics, Inc. (LCTX) halal? Not Halal. Based on AAOIFI screening, Lineage Cell Therapeutics, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Lineage Cell Therapeutics, Inc.

LCTX: Is Lineage Cell Therapeutics, Inc. Halal?

Not Halal

Lineage Cell Therapeutics, Inc.

AMEXHealthcareUS

$1.21

-4.35%

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Sector: Healthcare 路 Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 18, 2026
F

Non-Compliant

Fails Shariah screening

0Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Failed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap0.8% / 30.0%

Compliance History

Not Halal, unchanged since May 2026.

No status changes recorded since we began tracking.

Tracked since May 2026. Updates automatically on each re-screen.

Screened: Jun 18, 2026Fiscal: Q1 2026Source: EDGAR

Financial Overview

Market Cap

301.7M

Price

$1.21

Sector

Healthcare

Industry

Biotechnology

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

00
0001.KLA+

Supercomnet Technologies Bhd

$0.54

+0.00%

00
0002.KLA+

Kotra Industries Bhd

$3.75

+0.00%

00
0075.KLA+

LYC Healthcare Bhd

$0.02

+0.00%

01
0101.KLA+

TMC Life Sciences Bhd

$0.45

+0.00%

01
0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.27

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

A

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

A

PFE

Pfizer Inc.

F

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+
Free 路 No credit card required

Track LCTX and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started FreeBrowse Screener
10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Lineage Cell Therapeutics, Inc. (LCTX) halal to invest in?
Lineage Cell Therapeutics, Inc. (LCTX) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.
Why did Lineage Cell Therapeutics, Inc. get a F compliance rating?
Lineage Cell Therapeutics, Inc. (LCTX) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 0.8% (limit 30%); interest-bearing deposits of 20.4% (limit 30%); prohibited income of 28.15% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Lineage Cell Therapeutics, Inc.'s Shariah verdict?
Lineage Cell Therapeutics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Lineage Cell Therapeutics, Inc. re-screened for Shariah compliance?
Lineage Cell Therapeutics, Inc. (LCTX) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 18, 2026.

Screened according to AAOIFI Standard No. 21 路 For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.